December :
Authors explore pathways of myocyte toxicity due to antharcyclines by means of a translational study including a murine animal model and replicated on cardiomyocytes from a single leukemia patient. Their results increase our knowledge on the pathways of anthracyclin cardiotoxicity. Authors test the effect of IL-1α neutralizing antibodies with a positive effect on the murine model. Although their results need further research in humans, it opens new perspectives for cardioprotection beyond the classic heart failure therapies.
- Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study
- Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer
November :
- Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score
- Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
Our mission: To reduce the burden of cardiovascular disease.